We conducted a multicenter study at various Level 3 national centers in Dakar, including 16 medical departments and 3 departments of pathological anatomy. We screened all cases of amyloidosis confirmed by histology in patients over 16 years of age from January 1990 to October 2024.

Case recruitment was performed through two separate pathways:

1)Direct Hospital Record Review: A retrospective review of patient files from outpatient clinics and inpatient wards was performed using a pre-designed data collection form.

2)Scientific Literature Aggregation: An online literature review was conducted in PubMed, ScienceDirect, and African Journals OnLine (AJOL) using the keywords: amyloidosis,amyloid,Dakar,and black. A manual check of bibliographical references was performed. Out of 8 published case reports identified from Senegal, 3 were excluded because they were already captured within the hospital databases or lacked primary variables. To prevent double-counting or duplicating data from patients, deduplication was performed by cross-referencing patient initials, sex, age at diagnosis, year of admission, and the reporting hospital center.

To account for the limited access to immunophenotyping, all biochemical subtypes were systematically reclassified into three distinct diagnostic certainty categories based on the recommendations of the International Amyloidosis Society Committee [3][11]:

1) Confirmed Subtype: Formally established in the presence of positive immunohistochemistry and/or immunofluorescence using specific antibodies.

2)Probable Subtype: Assigned in the absence of typing, when a patient met all presumptive epidemiological, clinical phenotype, and etiological criteria according to international recommendations.

3)Indeterminate Subtype: Categorized when histologically proven amyloidosis lacked any prescriptive phénotypic or etiological evidence to support a specific biochemical protein.

The presumptive international criteria used to assign a Probable subtype were:

1)AA Amyloidosis: Nephrotic syndrome or chronic kidney disease, combined with an active or long-standing history of a chronic infectious disease (e.g., tuberculosis, leprosy) or a well-documented chronic autoinflammatory/autoimmune condition (e.g., rheumatoid arthritis).

2) AL Amyloidosis:Nephrotic syndrome, restrictive cardiomyopathy, macroglossia, or peripheral neuropathy, occurring in the presence of a serum/urinary monoclonal gammopathy or a clonal plasma cell population in the bone marrow.

3)Senile ATTR Amyloidosis:Patients aged 75 years or older presenting with predominant restrictive cardiomyopathy, in the complete absence of a detectable monoclonal gammopathy or family history of amyloidosis.

4)Genetic ATTR Amyloidosis:Sensorimotor axonal neuropathy or cardiomyopathy associated with autonomic dysfunction and a confirmed family history of hereditary systemic amyloidosis.

5)Beta-2-Microglobulin Amyloidosis:Long-term hemodialysis patients (on dialysis for more than 5 years) presenting with carpal tunnel syndrome, joint pain, or destructive arthropathy.

Visceral organ involvement was formally attributed to amyloidosis if tissue biopsy confirmed amyloid material or if clinical, biological, and non-invasive imaging findings were strongly suggestive of organ dysfunction as defined by international consensus guidelines, even in the absence of site-specific histological confirmation.

Statistical analysis was performed using Sphinx and SPSS software. Quantitative variables are presented as means ± standard deviations; qualitative variables as counts and percentages. Survival analysis was conducted using the Kaplan-Meier method to calculate the cumulative survival rate over time. Right-censoring was applied at the date of last known follow-up or at the end of the 36-month observation window. To manage the high rate of patients lost to follow-up (43.90%), a sensitivity analysis was performed by treating them as censored at their last contact date. Due to the limited number of documented deaths (n = 7), multivariate Cox regression analysis was treated as strictly exploratory, and no definitive long-term prognostic conclusions were drawn. Ethical clearance was obtained from the institutional boards, data were anonymized, and a waiver of written consent was granted for this retrospective chart review and literature public data analysis.

Forty-one cases were identified. This total reflects a single, verified master dataset comprised of 36 cases (87.80%) from direct hospital consultations and 5 cases (12.20%) from the aggregated literature review. The incidence of amyloidosis has been steadily increasing over the past decade. Our cohort consisted of 18 men and 23 women, yielding a male-to-female ratio of 0.78. The mean age at diagnosis was 59.93 ± 14.89 years (range: 24 to 83 years). Patients were primarily recruited from nephrology (39.02%, n = 16) and internal medicine (31.71%, n = 12) (Table 1). No family history of amyloidosis was found.

Table 1.Distribution of amyloidosis cases by referring specialty.

The most common reasons for consultation were lower extremity edema (60.98%, n = 25) and diffuse pain (39.02%, n = 16) (Table 2). Amyloidosis was systemic in 68.29% (n = 28) and localized in 31.71% (n = 13). The histological diagnosis was made based on a renal biopsy in 22 patients (53.65%), a salivary gland biopsy in 13 patients (31.70%), a skin biopsy in two patients (4.87%), a bronchial biopsy in one patient (2.44%), and via combined salivary gland and abdominal subcutaneous fat biopsy in three patients (7.31%) [12].

Table 2.Distribution of amyloidosis cases by reason for consultation.

Renal manifestations were reported in 31 cases (75.61%). Their presentation was dominated by a glomerular nephropathy syndrome (64.51%, n = 20), presenting as an impure nephrotic syndrome in 12 cases [13]. Chronic kidney disease was present in 51.61% (n = 16) of these patients, hypertension in 25.80% (n = 8), and microscopic hematuria in 58.06% (n = 18). Renal ultrasound revealed kidneys of normal size in 18 cases (58.06%), small kidneys in 2 cases (6.45%), and renal parenchymal structural changes in 3 cases (9.67%) (Table 3).

Table 3. Clinical and laboratory characteristics of renal manifestations.

Cardiac manifestations were observed in 20 cases (48.78%), symptomatic in 13 cases (65%), and dominated by dyspnea. Electrocardiogram (ECG) performed in 34 cases was abnormal in 30 patients, dominated by microvoltage in 44.12% (n = 15). Echocardiography performed in 21 patients revealed a suggestive pattern in 12 patients (57.14%), showing restrictive cardiomyopathy with predominant septal hypertrophy in 11 cases (52.38%) (Table 4) [14]. Cardiac MRI performed in 5 cases was helpful in 3 patients. No endomyocardial biopsies were performed.

Table 4. Clinical and paraclinical characteristics of cardiac manifestations.

Gastrointestinal manifestations were observed in 16 patients (39.02%); macroglossia was present in 2 cases (4.87%). Musculoskeletal manifestations were found in 13 patients (31.70%), dominated by polyarthritis (n = 8) (Figure 1). Neurological manifestations were found in 9 patients, presenting as sensorimotor polyneuropathy in 8 cases (19.51%) and carpal tunnel syndrome in 2 cases (4.88%) (Figure 2). Dermatological signs were present in 3 cases (7.31%), including periorbital hematomas (n = 2). Pulmonary manifestations were observed in 12 cases (29.26%).

Figure 1. Shoulder strap sign during AL amyloidosis (A: frontal view, B: lateral view).

Figure 2. Carpal tunnel syndrome.

Definitive immunophenotyping was successfully performed in only 3 cases, establishing a Confirmed diagnosis of AL amyloidosis in 2 cases (4.87%) and Confirmed AA amyloidosis in 1 case (2.43%). The remaining 38 patients were stratified into Probable or Indeterminate categories based on phenotype-etiology alignment.

Neoplastic disease (multiple myeloma) underlaid 34.14% (n = 14) of cases, followed by chronic infections in 24.39% (n = 10) and rheumatic/autoimmune diseases in 24.39% (n = 10). Tuberculosis alone accounted for 17.07% (n = 7) of cases (Table 5).

Table 5. Distribution of cases according to the different etiologies of amyloidosis.

Note: SPA: Ankylosing Spondylitis, FMF: Familial Mediterranean Fever, DADA2: Adenosine Deaminase 2 Deficiency, ARF: Acute Rheumatic Fever, RA: Rheumatoid Arthritis.

By correlating diagnostic certainty categories with biochemical types, our single dataset yielded: Confirmed AL in 2 cases, Confirmed AA in 1 case, Probable AA in 20 cases, Probable AL in 12 cases, Probable senile ATTR in 2 cases, Probable beta-2-microglobulin in 2 cases, and Indeterminate amyloidosis in 2 cases (Table 6). To meet the reviewers’ request, an analysis of sensitivity was performed: excluding the 5 literature-derived cases resulted in a cohorte of 36 hospital cases, within which the sub-type proportions remained statistically unchanged (AA: 52.77%, AL: 33.33%, ATTR: 5.55%, B2M: 5.55%, Indeterminate: 2.77%), proving that literature integration did not skew the local epidemiological landscape.

Table 6. Distribution of cases according to biochemical subtypes and certainty levels.

Therapeutic management was entirely symptomatic and etiology-directed: chemotherapy for multiple myeloma in 34.14% (n = 14), conventional immunosuppressants or corticosteroids in 51.21% (n = 21), and antituberculosis therapy in 17.07% (n = 7). Dialysis was required for 14.63% (n = 6) of patients.

Regarding patient follow-up, 12 patients (29.27%) are currently active, 18 patients (43.90%) were lost to follow-up, 4 patients (9.76%) were transferred out, and 7 patients (17.07%) died. The causes of death were heart failure (n = 2), septic shock secondary to catheter-related infections (n = 2), acute respiratory failure (n = 1), and unknown causes (n = 2). The 36-month cumulative survival rate was 60% (Figure 3). In the exploratory multivariate analysis, only advanced age was statistically associated with mortality (p = 0.023), with a survival rate of approximately 75% for patients under 80 years of age, whereas all patients over 80 years died during the follow-up period. Gender, biochemical certainty sub-types, and organ involvement did not show a statistically significant association with survival within this exploratory framework.

Figure 3. Overall patient follow-up curve.

The primary strength of this study lies in its multi-centric design over a 34-year inclusion span, providing the largest series documented in Senegal. However, the lack of widespread immunophenotyping represents a significant real-world challenge, reflecting a structural limitation shared by many sub-Saharan tertiary centers. This is primarily due to the fact that immunohistochemistry was only introduced in 2021 at the National Public Pathology Center, combined with a frequent shortage of specific reagents, the lack of cryostats for immunofluorescence, and high out-of-pocket costs for patients [10]. To avoid diagnostic overinterpretation, our systematic reclassification into Confirmed, Probable, and Indeterminate sub-types aligns with standard recommendations from the International Amyloidosis Nomenclature Committee [3][11]. By formalizing these definitions, we minimize classification error risks while capitalizing on highly specific clinical phénotypes and etiological links to characterize our cohort.

Globally, amyloidosis is reported to affect both sexes equally, though significant geographic variations exist. While several European and North American registries note a female predominance for AA amyloidosis and a male predominance for AL and ATTR forms [15][16], reports from North Africa and India frequently describe an overall male predominance [17]-[19]. Our cohort demonstrates a female predominance (M/F ratio 0.78), driven by the distribution of AA amyloidosis(12 females vs 9 males). The mean age at diagnosis of 59.93 years is consistent with data from Brazil (57 years) [20] and France (63 years) [21], but significantly higher than historical series from Morocco (39 years) [17] and Tunisia (48 years) [18]. This shift reflects an increasing life expectancy and the rising diagnosis of multiple myeloma-associated AL forms in our aging population [22][23].

Renal involvement was the predominant systemic manifestation (75.61%), presenting as a glomerular nephropathy syndrome with an impure nephrotic syndrome in 52% of renal cases. This high prevalence is consistent with literature indicating that renal tropism occurs in up to 90% of AA cases and 60% of AL cases [5][9][13]. Cardiac involvement, observed in 48.78% of our patients, manifested as a classic restrictive cardiomyopathy with septal hypertrophy, representing a major driver of mortality in AL and senile ATTR sub-types [14].

Etiologically, our findings reveal a co-dominance of neoplastic and chronic infectious/inflammatory diseases. While the incidence of AA amyloidosis has rapidly declined in Western nations due to highly effective cytokine-targeted therapies [24][25], it remains highly prevalent in developing countries [26]. In our series, chronic infectious etiologies underlaid all 21 AA cases, with tuberculosis alone accounting for 17.07% of the entire cohort. This matches historical reports from India and North Africa where infections remain the primary driver of secondary amyloidosis [17][19][27]. Conversely, all AL amyloidosis cases in our series were secondary to multiple myeloma, reflecting a distribution pattern that resembles high-resource country cohorts where hematological malignancies predominate [21][28], complemented by an autoimmune and autoinflammatory profile typical of African cohorts [29].

Our cumulative 36-month survival rate of 60% must be interpreted with caution. The exceptionally high rate of patients lost to follow-up (43.90%) represents a common limitation in retrospective sub-Saharan chart reviews, caused by structural deficiencies in patient tracking systems, financial constraints, or patients returning to rural areas [10]. By treating lost patients as right-censored within our Kaplan-Meier analysis, we minimize structural survival underestimation. The exploratory finding that advanced age remains the sole variable statistically associated with mortality (p = 0.023) highlights the vulnerability of elderly patients facing un-typed and non-specifically treated systemic amyloidosis in tropical settings.